Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the impact of raltegravir, maraviroc, darunavir/r, and
Truvada® (emtricitabine/tenofovir) vs. darunavir/r and Truvada® on cell-associated HIV-DNA
levels in patients with primary HIV-1 infection.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)